Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Capital Expenditures (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Capital Expenditures for 3 consecutive years, with $7000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures fell 84.09% to $7000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $25000.0 through Dec 2025, down 43.18% year-over-year, with the annual reading at $25000.0 for FY2025, 43.18% down from the prior year.
  • Capital Expenditures hit $7000.0 in Q3 2025 for Compass Therapeutics, down from $18000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $44000.0 in Q3 2024 to a low of $7000.0 in Q3 2025.
  • Historically, Capital Expenditures has averaged $16500.0 across 3 years, with a median of $10500.0 in 2023.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 340.0% in 2024 and later plummeted 84.09% in 2025.
  • Year by year, Capital Expenditures stood at $9000.0 in 2023, then surged by 388.89% to $44000.0 in 2024, then tumbled by 84.09% to $7000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CMPX at $7000.0 in Q3 2025, $18000.0 in Q1 2025, and $44000.0 in Q3 2024.